-
公开(公告)号：US20150299330A1
公开(公告)日：2015-10-22
申请号：US14790144
申请日：2015-07-02
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
公开(公告)号：US20130243795A1
公开(公告)日：2013-09-19
申请号：US13835518
申请日：2013-03-15
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
公开(公告)号：US20230047413A1
公开(公告)日：2023-02-16
申请号：US17747785
申请日：2022-05-18
Applicant: Janssen Biotech, Inc.
Inventor： Marc Mercken , Thomas Malia , Marianne Borgers , Kristof Van Kolen
Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and use of the antibodies for treating or preventing conditions such as tauopathies.
-
公开(公告)号：US20210179696A1
公开(公告)日：2021-06-17
申请号：US16986615
申请日：2020-08-06
Applicant: Janssen Biotech, Inc.
Inventor： Marc Mercken , Thomas Malia , Marianne Borgers , Kristof Van Kolen
Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
-
公开(公告)号：US20200277393A1
公开(公告)日：2020-09-03
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
Patent Agency Ranking
公开(公告)号：US09683046B2
公开(公告)日：2017-06-20
申请号：US14790144
申请日：2015-07-02
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US20150307600A1
公开(公告)日：2015-10-29
申请号：US14363888
申请日：2012-12-19
Applicant: Janssen Biotech, Inc.
Inventor： Christopher Alderfer , Dariusz Janecki , Xueson Liu , Melissa Murdock , Sheng-Jiun Wu , Marc Mercken , Marc Vandermeeren , Thomas Malia
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Anti-PHF-tau antibodies and methods of making and using them are disclosed.
Abstract translation: 公开了抗-PHF-tau抗体及其制备和使用方法。
-
公开(公告)号：US11732050B2
公开(公告)日：2023-08-22
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US11365244B2
公开(公告)日：2022-06-21
申请号：US16986615
申请日：2020-08-06
Applicant: Janssen Biotech, Inc.
Inventor： Marc Mercken , Thomas Malia , Marianne Borgers , Kristof Van Kolen
Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
-
公开(公告)号：US20170320957A1
公开(公告)日：2017-11-09
申请号：US15596609
申请日：2017-05-16
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.021 seconds)
